PMID- 28592065
OWN - NLM
STAT- MEDLINE
DCOM- 20180702
LR  - 20181202
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 97
IP  - 20
DP  - 2017 May 30
TI  - [Impact of adjuvant chemotherapy on the prognosis of hormone receptor negative 
      breast cancer with residual lymph node disease after neoadjuvant chemotherapy].
PG  - 1576-1579
LID - 10.3760/cma.j.issn.0376-2491.2017.20.015 [doi]
AB  - Objective: To explore the influence of adjuvant chemotherapy on the prognosis of 
      hormone receptor negative breast cancer with residual lymph node 
      disease(RLND)after neoadjuvant chemotherapy. Methods: A total of 110 hormone 
      receptor negative breast cancer patients treated with 4-8 cycles of neoadjuvant 
      chemotherapy were respectively analysed between 2002 and 2012. Residual lymph 
      node disease was comfirmed by subsequent radical mastectomy. Then all these 
      patients were classified into two groups: patients treated with adjuvant 
      chemotherapy(group A) and patients untreated with adjuvant chemotherapy(group B). 
      Results: All patients were female, the median age was 54.5 years old(IQR: 47-59 
      years). The median follow-up time was 61 months(IQR: 51-88 months). There were 82 
      patients (74.5%) in group A, and 28 patients (25.5%) in group B. The five-year 
      disease-free survival (DFS) rate was 76.2% in group A and 57.6% in group B. The 
      distant disease-free survival (DDFS) rate was 78.9% in group A and 60.4% in group 
      B. Overall survival (OS) rate was 81.0% in group A and 60.0% in group B. 
      Multivariate analysis showed that there were significant differences for DDFS 
      rate (group A vs group B, P=0.033; hazard ratio [HR], 5.256; 95% confidence 
      interval [95%CI], 1.14-24.17) and OS rates (group A vs group B, P=0.011; HR, 
      7.478; 95%CI, 1.58-35.30) between two groups. Conclusion: The patients who have 
      hormone receptor negative breast cancer with RLND after neoadjuvant chemotherapy, 
      may benefit from postoperative adjuvant chemotherapy.
FAU - Wang, X
AU  - Wang X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education), Breast Cancer Prevention and Treatment Center, Peking University 
      Cancer Hospital & Institute, Beijing 100143, China.
FAU - He, Y J
AU  - He YJ
FAU - Li, J F
AU  - Li JF
FAU - Xie, Y T
AU  - Xie YT
FAU - Wang, T F
AU  - Wang TF
FAU - Fan, Z Q
AU  - Fan ZQ
FAU - Ouyang, T
AU  - Ouyang T
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/surgery
MH  - *Chemotherapy, Adjuvant
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lymph Nodes
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Prognosis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Breast neoplasms
OT  - Lymph node
OT  - Neoadjuvant chemotherapy
OT  - Prognosis
EDAT- 2017/06/09 06:00
MHDA- 2018/07/03 06:00
CRDT- 2017/06/09 06:00
PHST- 2017/06/09 06:00 [entrez]
PHST- 2017/06/09 06:00 [pubmed]
PHST- 2018/07/03 06:00 [medline]
AID - 10.3760/cma.j.issn.0376-2491.2017.20.015 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2017 May 30;97(20):1576-1579. doi: 
      10.3760/cma.j.issn.0376-2491.2017.20.015.